Poolbeg Pharma's POLB 001 has great potential to generate significant value for shareholders

Poolbeg Pharma plc announces audited results for 2023, highlighting financial, corporate, and operational achievements. CEO Jeremy Skillington emphasizes potential for significant value creation.

Related Keywords

United States ,American ,Poolbeg Pharma ,Brendan Buckley ,Cathal Friel ,Amryt Pharma ,Jeremy Skillington ,Chiesi Farmaceutica ,American Society Of Hematology ,International Congress ,Nasdaq ,Professor Brendan Buckley ,Cytokine Release Syndrome ,Artificial Intelligence ,Scientific Advisory ,Respiratory Syncytial Virus ,American Society ,Annual Meeting ,Key Opinion Leaders ,Independent Advisory Board ,Chief Executive Officer ,